Clinical trials: Rituximab
Kidney Transplant Rejection, Antibody-mediated Rejection
Transplant Antibody-Mediated Rejection: Guiding Effective Treatments
This trial evaluates the addition of rituximab to standard of care in the treatment of antibody-mediated rejection in kidney transplant patients. The trial will involve adults and children.
- Trial name
- TAR:GET-1 (NCT03994783)
- Testing
- Rituximab, Methylprednisolone, Intravenous Immunoglobulin
- Where
- United Kingdom
- Volunteers
- 3 people
- Sponsor
- Imperial College London
Neuroblastoma, Opsoclonus-myoclonus
Use of Rituximab in Opsoclonus-Myoclonus in Children With Neuroblastoma
The purpose of this study is to evaluate the feasibility of giving four weekly doses of Rituximab (anti-CD20 antibody) in the treatment of children with refractory neuroblastoma associated opsoclonus-myoclonus.
- Trial name
- NCT00202930
- Testing
- anti-CD20 (Rituximab)
- Volunteers
- 4 people
- Sponsor
- Jean M. Tersak, M.D.
Follicular Lymphoma
Immunochemotherapy, Zevalin, and Bone Marrow Transplant for Follicular Lymphoma
Follicular lymphoma has historically been considered an incurable lymphoma. By combining multiple effective treatments, the investigators believe that prolonged disease-free survival is achievable in this disease.
- Trial name
- MasterPlan (NCT01130194)
- Testing
- Combination of treatment modalities
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- St. Louis University
Mature B-Cell Non-Hodgkin Lymphoma
A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma
The purpose of this study is to evaluate the safety and efficacy of glofitamab, as monotherapy and in combination with a standard chemoimmunotherapy regimen: rituximab, ifosfamide, carboplatin, and etoposide (R-ICE) in pediatric…
- Trial name
- iMATRIX GLO (NCT05533775)
- Testing
- Obinutuzumab, Glofitamab, Rituximab
- Where
- 30 sites in United States, Australia and 11 more
- Volunteers
- 65 people
- Sponsor
- Hoffmann-La Roche
Lymphoma, Indolent Non-hodgkin Lymphoma
MRD Guided De-intensification of Bendamustine/Rituximab for Indolent Non-Hodgkin Lymphoma
This is a phase II pilot, single arm, open label study designed to assess the efficacy, safety, and feasibility of MRD adapted duration of BR for untreated or R/R iNHL.
- Trial name
- NCT06557330
- Testing
- Bendamustine, Rituximab
- Volunteers
- 24 people
- Sponsor
- Fox Chase Cancer Center
Diffuse Large B-cell Lymphoma, de Novo DLBCL
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
The purpose of this study is to evaluate the efficacy of Pixantrone + Rituximab compared to Gemcitabine + Rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), or follicular grade 3 lymphoma.
- Conditions
- Diffuse Large B-cell Lymphoma, de Novo DLBCL, DLBCL Transformed From Indolent Lymphoma, Follicular Grade 3 Lymphoma
- Trial name
- PIX-R (NCT01321541)
- Testing
- Pixantrone + Rituximab, Gemcitabine + Rituximab
- Where
- 131 sites in United States, Austria and 15 more
- Volunteers
- 312 people
- Sponsor
- CTI BioPharma
Non-Hodgkin's Lymphoma
Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
The purpose of this study is to determine if the combination of VELCADE and rituximab improves progression free survival relative to rituximab alone in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (B-NHL)…
- Trial name
- NCT00312845
- Testing
- Bortezomib + Rituximab, Rituximab
- Where
- 206 sites in United States, Argentina and 30 more
- Volunteers
- 676 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Chronic Lymphocytic Leukemia
Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation
The aim of this study is to evaluate if standard chemoimmunotherapy (FCR, BR) in frontline treatment of physically fit CLL patients without del17p or TP 53 mutation can be replaced by combinations of targeted drugs (Venetoclax…
- Trial name
- GAIA (NCT02950051)
- Testing
- Fludarabine, Cyclophosphamide, Rituximab
- Where
- 161 sites in Austria, Belgium and 8 more
- Volunteers
- 926 people
- Sponsor
- German CLL Study Group
Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma
Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma
This phase II trial studies the side effects of an escalated ramp-up of sonrotoclax following initial debulking with zanubrutinib or rituximab in treating patients with chronic lymphocytic leukemia (CLL), small lymphocytic…
- Conditions
- Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Mantle Cell Lymphoma
- Trial name
- NCT06839053
- Testing
- Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Fred Hutchinson Cancer Center
Non-Hodgkin's Lymphoma
Personalized Active Immunotherapy (Vaccine Therapy) and Sargramostim Given After Standard of Care Treatment With Rituximab and Chemotherapy for Initial Treatment With Lymphoma
The treatment being investigated is a patient- and tumor-specific therapy known as a personalized active immunotherapy. Personalized active immunotherapy is an attempt to use a person's own immune system to combat disease.
- Trial name
- NCT00510471
- Testing
- autologous immunoglobulin idiotype-KLH conjugate vaccine
- Where
- 9 sites in United States
- Sponsor
- Genitope Corporation
Lymphoma, B-Cell
Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma
This is a Phase 1b/2 randomized study of Iberdomide (CC-220) added to 3 different combination regimens (polatuzumab vedotin plus rituximab (Cohort A), tafasitamab (Cohort B), rituximab plus gemcitabine and platinum-based…
- Trial name
- NCT04882163
- Testing
- CC-220, Polatuzumab vedotin, Rituximab
- Where
- 27 sites in United States, Austria and 6 more
- Sponsor
- Celgene
Acquired Immunodeficiency
Safety, Tolerability and Immunogenicity of 4CMenB Vaccine(2 Doses) in Adults With an Immunodeficiency
The meningococcal quadrivalent conjugate vaccine (MenACWY) and the licenced multicomponent MenB vaccine (Bexsero®) have already been included in the Italian childhood immunization programme and recommendations for high risk…
- Trial name
- 4CMenB (NCT04295733)
- Testing
- 4CMenB (Bexsero®) vaccine
- Where
- Italy
- Volunteers
- 98 people
- Sponsor
- Ospedale Policlinico San Martino
Lymphoma, Non-Hodgkin, Advanced Stage Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Tailoring Treatment for B Cell Non-hodgkin's Lymphoma Based on PET Scan Results Mid Treatment
The purpose of this study is to assess whether patients who are likely to fail R-CHOP, as predicted by a mid-treatment PET scan, can have an improved outcome if switched to a standard salvage regimen R-ICE (rituximab, ifosfamide…
- Trial name
- LYTPET (NCT00324467)
- Testing
- Cyclophosphamide, Doxorubicin, Vincristine
- Where
- Canada
- Volunteers
- 150 people
- Sponsor
- British Columbia Cancer Agency
Systemic Lupus Erythematosus
Cyclophosphamide and Rabbit Antithymocyte Globulin (rATG)/Rituximab in Patients With Systemic Lupus Erythematosus
This study is designed to examine whether treating patients with lupus with high dose cyclophosphamide together with rATG/rituximab (drugs which reduce the function of the immune system), followed by return of their previously…
- Trial name
- NCT00278538
- Testing
- Hematopoietic stem cell transplantation
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- Northwestern University
Lymphoma
Zevalin (Ibritumomab Tiuxetan) for Early Stage Indolent Lymphomas
The goal of this clinical research study is to find out if giving (Rituxan) rituximab with 90Y (ibritumomab tiuxetan) (90 Y Zevalin®) may be effective in treating low-grade lymphoma.
- Trial name
- NCT00493467
- Testing
- Ibritumomab Tiuxetan (Zevalin), Rituximab
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- M.D. Anderson Cancer Center
Nodular Lymphocyte Predominant B-Cell Lymphoma, Recurrent Nodular Lymphocyte Predominant B-Cell Lymphoma
Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial
This phase II trial compares mosunetuzumab to the usual treatment (rituximab) for improving survival in patients with nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL). Rituximab and mosunetuzumab are monoclonal antibodies.
- Conditions
- Nodular Lymphocyte Predominant B-Cell Lymphoma, Recurrent Nodular Lymphocyte Predominant B-Cell Lymphoma, Refractory Nodular Lymphocyte Predominant B-Cell Lymphoma
- Trial name
- NCT05886036
- Testing
- Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy
- Where
- 37 sites in United States, Canada
- Volunteers
- 70 people
- Sponsor
- National Cancer Institute (NCI)
Waldenstrom Macroglobulinemia
Thalidomide, Lenalidomide, and Rituximab for Previously Treated Waldenstrom Macroglobulinemia
The purpose of this study is to evaluate the efficacy and safety of daily alternating thalidomide and lenalidomide plus rituximab (ThRiL) in patients with previously treated Waldenstrom macroglobulunemia (WM).
- Trial name
- THRiL for WM (NCT01779167)
- Testing
- Thalidomide, Lenalidomide, Rituximab
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Weill Medical College of Cornell University
Rheumatoid Arthritis
A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a Single Anti-TNF Inhibitor
This study will evaluate the efficacy and safety of MabThera in patients with active rheumatoid arthritis who have had an inadequate response to one prior anti-TNF alpha inhibitor.
- Trial name
- NCT02079532
- Testing
- rituximab [MabThera]
- Where
- 69 sites in Germany
- Volunteers
- 302 people
- Sponsor
- Hoffmann-La Roche
Mantle Cell Lymphoma
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
This phase III trial tests whether continuous or intermittent zanubrutinib after achieving a complete remission (CR) with rituximab works in older adult patients with mantle cell lymphoma (MCL) who have not received treatment in…
- Trial name
- NCT05976763
- Testing
- Zanubrutinib, Rituximab, Patient Observation
- Where
- 238 sites in United States
- Volunteers
- 421 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Lymphoma, AIDS-related, Lymphoma, Large B-Cell, Diffuse
EPOCH and Rituximab to Treat Non-Hodgkin's Lymphoma in Patients With HIV Infection
Background: Human immunodeficiency virus (HIV)-infected patients have a weakened immune system, and chemotherapy, which is used to treat lymphoma, probably causes further damage to the immune system.
- Trial name
- NCT00006436
- Testing
- Rituximab, Filgrastim, EPOCH
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- National Cancer Institute (NCI)